DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,345,766 B2 Zhang Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,345,766 B2 Zhang Et Al USOO934,5766 B2 (12) United States Patent (10) Patent No.: US 9,345,766 B2 Zhang et al. (45) Date of Patent: *May 24, 2016 (54) COMBINATION THERAPIES COMPRISING (58) Field of Classification Search ANT-ERBB3 AGENTS USPC ..................................... 424/136.1:530/387.3 See application file for complete search history. (71) Applicant: Merrimack Pharmaceuticals, Inc., Cambridge, MA (US) (56) References Cited (72) Inventors: Bo Zhang, Lynnfield, MA (US); Charlotte McDonagh, Winchester, MA U.S. PATENT DOCUMENTS (US); Alexandra Huhalov, Cambridge, MA (US) 4.450,103 A 5/1984 Konrad et al. 4,588,585 A 5/1986 Market al. 4,704,692 A 11/1987 Ladner (73) Assignee: Merrimack Pharmaceuticals, Inc., 4,737.462 A 4, 1988 Market al. Cambridge, MA (US) 4,816,567 A 3/1989 Cabilly et al. 4.946,778 A 8, 1990 Ladner et al. (*) Notice: Subject to any disclaimer, the term of this $25 A 23: Mark et al patent is extended or adjusted under 35 5,132,405W-1 r. A 7, 1992 HustonustOn et al. U.S.C. 154(b) by 0 days. 5,168,062 A 12/1992 Stinski 5,258.498 A 11/1993 Huston et al. This patent is Subject to a terminal dis- 5,260,203 A 11/1993 Ladner et al. claimer. 5,292,658 A 3, 1994 Cormier et al. 5,385,839 A 1/1995 Stinski (21) Appl. No.: 14/015,776 (Continued) (22) Filed: Aug. 30, 2013 FOREIGN PATENT DOCUMENTS (65) Prior Publication Data AU 61.2370 B 12, 1988 US 2014/0079703 A1 Mar. 20, 2014 AU 648591 B 2/1992 (Continued) Related U.S. Application Data OTHER PUBLICATIONS (60) Provisional application No. 61/695.242, filed on Aug. 30, 2012. Oyama et al. (Cancer Res, Apr. 15, 2011, 71. Abstract No. 654).* (Continued) (51) Int. Cl. A 6LX39/395 (2006.01) CR '7. 3.08: Primary Examiner — Yan Xiao A6 IK3I/565 (2006.015 (74) Attorney, Agent, or Firm — Clark & Elbing LLP A6 IK3I/38 (2006.01) A6 IK3I/496 (2006.01) A 6LX3/57 (2006.01) (57) ABSTRACT A6 IK33/24 (2006.01) Disclosed are methods and compositions for inhibiting the g 448 3. growth of a tumor (e.g., a malignant tumor) in a Subject. In A6 IK3I/337 30 6. 8: particular, combination therapies for treating a tumor in a A6 IK3I/436 (200 6,015 Subject by co-administering an agent selected from i) an A 6LX3/59 (2006.015 effective amount of an anti-estrogen agent; ii) an effective A6 IK3I/567 (2006.015 amount of a receptor tyrosine kinase inhibitor; iii) an effective C07K 6/28 (2006.01) amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective C07K 6/40 (2006.01) amount of MM-151; v) an effective amount of an mTOR A61 K39/00 (2006.01) inhibitor; and/or vi) an effective amount of trastuzumab or (52) U.S. Cl. TMD1, and/or combinations thereof, and an effective amount CPC ........... A61K.39/3955 (2013.01); A61K31/138 of a bispecific anti-ErbB2/anti-ErbB3 antibody. Also dis (2013.01); A61 K3I/337 (2013.01); A61 K closed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use 3 1/4 196 (2013.01); A61 K31/436 (2013.01): in the therapy of a tumor in combination with an agent A6 IK3I/517 (2013.01); A61 K3I/519 selected fromi) an effective amount of an anti-estrogen agent; (2013.01); A61 K3I/565 (2013.01); A61 K ii) an effective amount of a receptor tyrosine kinase inhibitor; 3 1/567 (2013.01); A61 K3I/7068 (2013.01): iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; A61 K33/24 (2013.01); A61K 39/39558 iv) an effective amount of MM-151; v) an effective amount of (2013.01); A61K 45/06 (2013.01); C07K an mTOR inhibitor; and/or vi) an effective amount of trastu I6/2863 (2013.01); C07K 16/32 (2013.01); Zumab or TMD1, and/or combinations thereof. C07K 16/40 (2013.01); C07K 16/468 (2013.01); A61 K 2039/505 (2013.01); A61 K 2039/507 (2013.01); C07K 23.17/31 (2013.01) 5 Claims, 39 Drawing Sheets US 9,345,766 B2 Page 2 (56) References Cited 6,686,179 B2 2/2004 Fleer et al. 6,692.942 B2 2/2004 Filpula et al. U.S. PATENT DOCUMENTS 6,743,896 B2 6/2004 Filpula et al. 6,743,908 B2 6/2004 Filpula et al. 5,455,030 A 10/1995 Ladner et al. 6,764,853 B2 7/2004 Filpula et al. 5,476.786 A 12/1995 Huston 6,806,365 B2 10/2004 Chen et al. 5,482,858 A 1/1996 Huston et al. 6,818,216 B2 11/2004 Young et al. 5,518,889 A 5, 1996 Ladner et al. 6,835,738 B1 12/2004 Brown et al. 5,525,491 A 6, 1996 Huston et al. 6,855,706 B2 2/2005 Satake et al. 5.530,101 A 6/1996 Queen et al. 6,872,719 B1 3/2005 Brown et al. 5,534,254 A 7, 1996 Huston et al. 6,878,718 B2 4/2005 Brand et al. 5,534,621 A 7, 1996 Ladner et al. 6,903,128 B2 6/2005 Duplantier et al. 5,612, 196 A 3/1997 Becquartet al. 6,905,688 B2 6/2005 Rosen et al. 5,622,701 A 4/1997 Berg 6,911,451 B1 6/2005 Porter et al. 5,631,158 A 5, 1997 Dorai et al. 6,916.933 B2 7/2005 Kaplanet al. 5,656,730 A 8, 1997 Lee 6,926,898 B2 8, 2005 Rosen et al. 5,658.763. A 8, 1997 Dorai et al. 6,946,134 B1 9, 2005 Rosen et al. 5670,356 A 9/1997 Shefetal. 6,962.978 B2 11/2005 Pepinsky et al. 5,730,978 A 3/1998 Wayner 6,972,322 B2 12/2005 Fleer et al. 5,733,782. A 3, 1998 Dorai et al. 6,987.006 B2 1/2006 Fleer et al. 5,738.845 A 4, 1998 Imakawa 6,989,365 B2 1/2006 Fleer et al. 5,753.204 A 5, 1998 Huston et al. 6,994,857 B2 2/2006 Rosen et al. 5,753,637 A 5, 1998 Albert et al. 7,015,216 B2 3/2006 Konradi et al. 5,763,733 A 6, 1998 Whitlow et al. 7,045,318 B2 5 2006 Ballance 5,766,883. A 6, 1998 Ballance et al. 7,067,313 B1 6/2006 Jacquemin et al. 5,767.260 A 6, 1998 Whitlow et al. 7,105,520 B2 9, 2006 Suzuki et al. 5.780594 A 7, 1998 Carter 7,141,547 B2 11/2006 Rosen et al. 5,800.815 A 9, 1998 Chestnut et al. 7,153,963 B2 12/2006 Makino et al. 5,821,231. A 10/1998 Arrhenius et al. 7,160.874 B2 1/2007 Tanaka et al. 5,837,846 A 1 1/1998 Huston et al. 7,183,092 B2 2/2007 Choi et al. 5,840,299 A 1 1/1998 Bendig et al. 7,189,.690 B2 3/2007 Rosen et al. 5,856,456 A 1/1999 Whitlow et al. 7,193,108 B2 3/2007 Chiba et al. 5,869,448 A 2f1999 Arrhenius et al. 7,238,344 B2 7/2007 Pedersen et al. 5,869.620 A 2f1999 Whitlow et al. 7,238,660 B2 7/2007 Rosen et al. 5874,540 A 2f1999 Hansen et al. 7,238,667 B2 7/2007 Rosen et al. 5,876,969 A 3, 1999 Fleer et al. 7,250,516 B2 7/2007 OkuZumi et al. 5.914,110 A 6, 1999 Holmes et al. 7,291645 B2 11/2007 Konradietal. 5917021 A 6, 1999 Lee 7.332.580 B2 2/2008 Adams et al. 5,928,904 A 7, 1999 Holmes et al. 7.332.585 B2 2/2008 Adams et al. 5.936.065 A 8, 1999 Arrhenius et al. 7,482,013 B2 1/2009 Ballance et al. 567,332 A 11/1999 Marks et al. 8,691,771 B2 4/2014 Nielsen et al. 5.990,275 A 1 1/1999 Whitlow et al. 8,927,694 B2 1/2015 McDonagh et al. 6,025,165 A 2/2000 Whitlow et al. 2002fOO31508 A1 3/2002 Wagner et al. 6,027.725 A 2/2000 Whitlow et al. 2002/0107284 A1 8, 2002 Uckun et al. 6,033,665 A 3, 2000 Yednock 2002fO151011 A1 10, 2002 Fleer et al. 6,103,889 A 8, 2000 Whitlow et al. 2003,000496 A1 1/2003 Duplantier et al. 6 21424 A 9, 2000 Whitlow et al. 2003, OO1801.6 A1 1/2003 Adams et al. 6,171,809 B1 1/2001 Roelant 2003/0022308 A1 1/2003 Fleer et al. 6 19269 B1 2/2001 Pollocket al. 2003.0036170 A1 2/2003 Fleer et al. 6,197.794 Bi 3/2001 Headeral. 2003.0036172 A1 2/2003 Fleer et al. 6,207,804 B1 3/2001 Hustonet al. 2003/0054554 A1 3/2003 Becquartet al. 6.20,670 B1 4/2001 Berg 2003/0054994 A1 3/2003 Noteborn et al. 6.229,011 B1 5, 2001 Chen et al. 2003/0078249 A1 4/2003 Baldwin et al. 6.265 572 B 7200 Cheneral. 2003/0082747 A1 5.2003 Fleer et al. 6.288.267 B1 9/2001 Hullet al.
Load more

Recommended publications
  • The Effects of Targeted Deletion of the Aromatase Enzyme on Prostatic Contractile Responses to Noradrenaline in Mice
    495 The effects of targeted deletion of the aromatase enzyme on prostatic contractile responses to noradrenaline in mice Katherine T Gray, Jennifer L Short, Evan R Simpson1 and Sabatino Ventura Prostate Research Co-operative, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia 1Prince Henry’s Institute of Medical Research, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia (Correspondence should be addressed to S Ventura; Email: [email protected]) Abstract This investigation aimed to see whether a change in the concentration-dependent contractions. Prazosin (0.3 mM) oestrogen to androgen ratio alters prostate contractility. Isolated attenuated the responses induced by noradrenaline and EFS in organ bath studies using prostates from aromatase knockout all mice (P%0.019, nZ5–7), while cocaine (10 mM) attenuated (ArKO) mice which were homozygous (ArKOK/K)and the responses evoked by tyramine (P!0.001, nZ6). There were heterozygous (ArKOC/K) for the disrupted aromatase cyp19 no genotype differences in EFS- and noradrenaline-induced gene and wild-type littermates (ArKOC/C) were conducted. responses (PR0.506, nZ10–13). Prostates from ArKOK/K The distribution of noradrenergic nerves was visualized using and ArKOC/K mice were more sensitive to tyramine than the sucrose–potassium phosphate–glyoxylic acid method. prostates from ArKOC/C mice (P!0.001, nZ11–13). Dense ArKOK/K mice had increased prostate weights compared adrenergic innervation of the prostate was similar in all mice. with ArKOC/C mice. Frequency–response curves to electrical These results suggest that although the absence of aromatase field stimulation (EFS; 0.5 ms pulse duration, 60 V,0.1–20 Hz) increases prostatic growth, this translates only to a subtle and yielded frequency-dependent contractions, while noradrenaline selective increase in contractility in mature mice.
    [Show full text]
  • Research in Your Backyard Developing Cures, Creating Jobs
    Research in Your Backyard Developing Cures, Creating Jobs PHARMACEUTICAL CLINICAL TRIALS IN ILLINOIS Dots show locations of clinical trials in the state. Executive Summary This report shows that biopharmaceutical research com- Quite often, biopharmaceutical companies hire local panies continue to be vitally important to the economy research institutions to conduct the tests and in Illinois, and patient health in Illinois, despite the recession. they help to bolster local economies in communities all over the state, including Chicago, Decatur, Joliet, Peoria, At a time when the state still faces significant economic Quincy, Rock Island, Rockford and Springfield. challenges, biopharmaceutical research companies are conducting or have conducted more than 4,300 clinical For patients, the trials offer another potential therapeutic trials of new medicines in collaboration with the state’s option. Clinical tests may provide a new avenue of care for clinical research centers, university medical schools and some chronic disease sufferers who are still searching for hospitals. Of the more than 4,300 clinical trials, 2,334 the medicines that are best for them. More than 470 of the target or have targeted the nation’s six most debilitating trials underway in Illinois are still recruiting patients. chronic diseases—asthma, cancer, diabetes, heart dis- ease, mental illnesses and stroke. Participants in clinical trials can: What are Clinical Trials? • Play an active role in their health care. • Gain access to new research treatments before they In the development of new medicines, clinical trials are are widely available. conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug • Obtain expert medical care at leading health care Administration to approve treatments.
    [Show full text]
  • Isolation and Characterization of a Chinese Hamster Ovary Cell Line Resistant to Bifunctional Nitrogen Mustards1
    [CANCER RESEARCH 46, 6290-6294, December 1986] Isolation and Characterization of a Chinese Hamster Ovary Cell Line Resistant to Bifunctional Nitrogen Mustards1 Craig N. Robson, Janice Alexander, Adrian L. Harris, and Ian D. Hickson2 Departmem of Clinical Oncology, University of Newcastle upon Tyne, The Royal Victoria Infirmary, Newcastle upon Tyne, NEI 4LP, United Kingdom ABSTRACT mustards, is collaterally sensitive to nitrosoureas (10), despite the fact that both these classes of agent generate DNA inter- A drug-resistant derivative of a Chinese hamster ovary cell line has strand cross-links. been generated by chronic exposure to progressively higher concentra Although chlorambucil is widely used in the curative therapy tions of chlorambucil. The cells exhibit greater than 20-fold resistance of Hodgkin's disease (11), in modified cyclophosphamide-meth- to the cytotoxic effects of chlorambucil and comparable levels of cross- resistance to mechlorethamine and melphalan. These drugs all belong to otrexate-5-fluorouracil protocols for breast cancer (12), in ovar a class of bifunctional alkylating agents which generate DNA cross-links ian cancer (13), and in small cell lung cancer (14), cell lines by reaction at the N-7 position of guanine. However, no resistance is isolated on the basis of chlorambucil resistance have rarely been observed to several other drugs which possess a similar mechanism of reported (15). action, to en-platinum (Mamminedichloride or to bischloroethylnitrosou- Here, we describe the isolation of a CHO3 cell line which rea and mitomycin C, which cross-link DNA via the O6 position of exhibits elevated levels of resistance to the cytotoxic effects of guaninc.
    [Show full text]
  • FLT3 Inhibitors in Acute Myeloid Leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2*
    Wu et al. Journal of Hematology & Oncology (2018) 11:133 https://doi.org/10.1186/s13045-018-0675-4 REVIEW Open Access FLT3 inhibitors in acute myeloid leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2* Abstract FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents. Keywords: FMS-like tyrosine kinase 3 inhibitors, Acute myeloid leukemia, Midostaurin, FLT3 Introduction RAS, MEK, and PI3K/AKT pathways [10], and ultim- Acute myeloid leukemia (AML) remains a highly resist- ately causes suppression of apoptosis and differentiation ant disease to conventional chemotherapy, with a me- of leukemic cells, including dysregulation of leukemic dian survival of only 4 months for relapsed and/or cell proliferation [11]. refractory disease [1]. Molecular profiling by PCR and Multiple FLT3 inhibitors are in clinical trials for treat- next-generation sequencing has revealed a variety of re- ing patients with FLT3/ITD-mutated AML. In this re- current gene mutations [2–4]. New agents are rapidly view, we summarized the preclinical and clinical studies emerging as targeted therapy for high-risk AML [5, 6]. on new FLT3 inhibitors, including sorafenib, lestaurtinib, In 1996, FMS-like tyrosine kinase 3/internal tandem du- sunitinib, tandutinib, quizartinib, midostaurin, gilteriti- plication (FLT3/ITD) was first recognized as a frequently nib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG mutated gene in AML [7].
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Chemotherapy for Metastatic Breast Cancer (MBC)
    Clinical Conversations Between an Oncology Nurse and Oncology Pharmacist During the Treatment of Patients With Breast Cancer: A Focus on Oral Chemotherapeutic Formulations © 2020. All rights reserved. No part of this report may be reproduced or distributed without the expressed written permission of PTCE. Faculty Information Chair Danielle Roman, PharmD, BCOP Manager, Clinical Pharmacy Services Allegheny Health Network Pittsburgh, Pennsylvania Allison Butts, PharmD, BCOP Kandra Horne, DNP, APRN, WHNP-BC Clinical Coordinator, Oncology Pharmacy Women’s Health Care Nurse Practitioner UK HealthCare Breast and GYN Oncology: Medical Oncology Assistant Adjunct Professor Winship Cancer Institute: Emory Healthcare UK College of Pharmacy Atlanta, Georgia Lexington, Kentucky This activity is supported by an educational grant from Athenex. Educational Objectives At the completion of this activity, participants will be able to: • Distinguish optimized treatment approaches for breast cancer based on disease- and patient-specific factors and potential places in therapy for oral formulations • Analyze the results of recent clinical trials with recently approved and emerging treatment options to inform the appropriate management of adverse effects and adherence for patients with breast cancer • Examine the benefits of multidisciplinary care across multiple practice environments for patients with breast cancer to optimize patient outcomes Evolving Oral Chemotherapeutic Opportunities in Breast Cancer Care Danielle Roman, PharmD, BCOP Manager, Clinical Pharmacy
    [Show full text]
  • Supplemental Table
    Supplementary Information DMD-AR-2020-000131 Evaluation of the disconnect between hepatocyte and microsome intrinsic clearance and in vitro in vivo extrapolation performance. Beth Williamson, Stephanie Harlfinger, Dermot F McGinnity Drug Metabolism and Pharmacokinetics, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK. Table S1. Compound physicochemical properties and in vitro ADME data. ACD ACD ACD Human Hep CLint Human Mic CLint Human Main Name MW Ion Class HBD HBA TPSA LogD 6 fuinc pKa A1 pKa B1 LogP (µL/min/x10 ) (µL/min/mg) fup isoform Chlorpromazine 318.9 Base 2 32 9.6 3.4 5.4 20 39 0.060 0.026 CYP2D6 Prochlorperazine 374.0 Base 3 35 7.7 3.6 4.8 12 2 0.023 0.141 CYP2D6 Dipyridamole 504.6 Neutral 4 12 145 6.5 3.8 0.3 28 96 0.407 0.048 UGT Erlotinib 393.4 Neutral 1 7 75 5.5 3.3 3.0 5 20 0.504 0.052 CYP3A Promethazine 284.4 Base 2 32 9.1 2.8 4.6 9 1 0.144 0.090 CYP2D6 Propranolol 259.4 Base 2 3 41 9.5 1.3 3.3 10 29 0.467 0.243 CYP2D6 Rosiglitazone 357.4 Neutral 1 5 97 6.3 6.5 2.5 2.8 13 37 0.514 0.003 Other Ondansetron 293.4 Base 4 40 6.8 1.6 2.8 3 8 0.842 0.435 CYP3A Amsacrine 393.5 Neutral 2 5 89 8.2 3.1 3.2 11 40 0.434 0.007 CYP1A Antazoline 265.4 Base 1 3 28 10.3 1.4 3.6 52 195 0.726 0.562 CYP3A Gefitinib 446.9 Base 1 7 69 7.0 3.7 3.7 4 44 0.214 0.035 CYP3A Edaravone 174.2 Neutral 1 3 33 2.7 0.5 1.1 2 65 0.828 0.001 UGT Semaxanib 238.3 Neutral 2 2 45 13.2 1.5 3.4 3.0 28 68 0.036 0.031 CYP3A Verapamil 454.6 Base 6 64 8.1 2.6 4.0 23 180 0.548 0.155 CYP3A Imatinib 493.6 Base 2 7 86 13.3 7.6 2.5 3.1 3 35 0.405
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Characterization of the Small Molecule Kinase Inhibitor SU11248 (Sunitinib/ SUTENT in Vitro and in Vivo
    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Genetik Characterization of the Small Molecule Kinase Inhibitor SU11248 (Sunitinib/ SUTENT in vitro and in vivo - Towards Response Prediction in Cancer Therapy with Kinase Inhibitors Michaela Bairlein Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ. -Prof. Dr. K. Schneitz Prüfer der Dissertation: 1. Univ.-Prof. Dr. A. Gierl 2. Hon.-Prof. Dr. h.c. A. Ullrich (Eberhard-Karls-Universität Tübingen) 3. Univ.-Prof. A. Schnieke, Ph.D. Die Dissertation wurde am 07.01.2010 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 19.04.2010 angenommen. FOR MY PARENTS 1 Contents 2 Summary ................................................................................................................................................................... 5 3 Zusammenfassung .................................................................................................................................................... 6 4 Introduction .............................................................................................................................................................. 8 4.1 Cancer ..............................................................................................................................................................
    [Show full text]
  • Section B Changed Classes/Guidelines Final
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2019 Section B Changed Classes/Guidelines Final Version Date of issue: 24th December 2018 1 A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS R2003 A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS R1993 Includes all plain synthetic and natural antispasmodics and anticholinergics. A3B Out of use; can be reused. A3C ANTISPASMODIC/ATARACTIC COMBINATIONS This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4. A3D ANTISPASMODIC/ANALGESIC COMBINATIONS R1997 This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1. A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS r2011 Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here. A3F GASTROPROKINETICS r2013 This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9. Combinations of gastroprokinetics with other substances
    [Show full text]
  • Using Next-Generation Sequencing to Find Targetable Genomic Lesions in a Case of Relapsed Extramedullary Acute Myeloid Leukemia
    Open Access Annals of Hematology & Oncology Case Report Using Next-Generation Sequencing to Find Targetable Genomic Lesions in a Case of Relapsed Extramedullary Acute Myeloid Leukemia Miller KC, Dias AL, Patnaik MM and Litzow MR* Division of Hematology, Mayo Clinic, USA Abstract *Corresponding author: Litzow MR, Division of Next-generation sequencing (NGS) has catalyzed a revolution in our Hematology, Mayo Clinic, Rochester, MN, 200 First understanding and treatment of leukemia, in some cases revealing cryptic Street SW, Rochester, MN 55905, USA genomic alterations that can be specifically targeted with drugs, such as tyrosine kinase inhibitors (TKIs). Herein we describe a case of relapsed extramedullary Received: January 15, 2017; Accepted: February 17, acute myeloid leukemia (AML), for which NGS of a tumor biopsy revealed 2017; Published: February 20, 2017 several genomic lesions, including an uncommon ETV6-ABL1 fusion oncogene. Consequently, we began treatment with the TKI dasatinib, in combination with 5-azacitidine. This report demonstrates the clinical value of using NGS to find targeted therapies for patients with hematological malignancies such as AML. Keywords: Extramedullary acute myeloid leukemia; Myeloid sarcoma; ETV6-ABL1; Dasatinib; Next-generation sequencing (NGS) Introduction (dim, variable), and myeloperoxidase (partial). Ki67 proliferative staining was high at approximately 90%. Bone marrow (BM) biopsy Next-generation sequencing (NGS) technology is rapidly demonstrated 4% myeloid blasts. Cytogenetic studies from the BM evolving, and has begun to unravel the unique complexities of aspirate showed complex cytogenetic abnormalities with six out of 20 hematologic malignancies. Using this technology, there has been metaphases demonstrating +8, +20, deletion 9p, deletion 16p, and a a recent, robust effort to parse hematologic diseases such as acute balanced translocation between chromosomes 1 and 11.
    [Show full text]
  • INTERRELATIONSHIPS of the ESTROGEN-PRODUCING ENZYMES NETWORK in BREAST CANCER DISSERTATION Presented in Partial Fulfillment Of
    INTERRELATIONSHIPS OF THE ESTROGEN-PRODUCING ENZYMES NETWORK IN BREAST CANCER DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Wendy L. Rich, M.S. ∗∗∗∗∗ The Ohio State University 2009 Dissertation Committee: Approved by Pui-Kai Li, Ph.D., Adviser Robert W. Brueggemeier, Ph.D. Karl A. Werbovetz, Ph.D. Adviser Graduate Program in Pharmacy Charles L. Shapiro M.D. ABSTRACT In the United States, breast cancer is the most common non-skin malignancy and the second leading cause of cancer-related death in women. However, earlier detection and new, more effective treatments may be responsible for the decrease in overall death rates. Approximately 60% of breast tumors are estrogen receptor (ER) positive and thus their cellular growth is hormone-dependent. Elevated levels of estrogens, even in post- menopausal women, have been implicated in the development and progression of hormone-dependent breast cancer. Hormone therapies seek to inhibit local estrogen action and biosynthesis, which can be produced by pathways utilizing the enzymes aromatase or steroid sulfatase (STS). Cyclooxygenase-2 (COX-2), typically involved in inflammation processes, is a major regulator of aromatase expression in breast cancer cells. STS, COX-2, and aromatase are critical for estrogen biosynthesis and have been shown to be over-expressed in breast cancer. While there continues to be extensive study and successful design of potent aromatase inhibitors, much remains unclear about the regulation of STS and the clinical applications for its selective inhibition. Further studies exploring the relationships of STS with COX-2 and aromatase enzymes will aid in the understanding of its role in cancer cell growth and in the development of future hormone- dependent breast cancer therapies.
    [Show full text]